A. J. Wood

发表

Drug Interactions in Hypertension

A. Wood, A. J. Wood, 1988, Hypertension.

Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects

C. Lang, C. Stein, A. Wood, 1996, Clinical pharmacology and therapeutics.

Dietary sodium intake modulates systemic but not forearm norepinephrine release

C. Stein, A. Wood, H. He, 1995, Clinical pharmacology and therapeutics.

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A

R. Kim, J. Groopman, M. Kinirons, 1999, Clinical pharmacology and therapeutics.

Ethnic differences in response to morphine

Margaret Wood, J. Sheller, H. Zhou, 1993 .

Differing effect of atropine on heart rate in Chinese and white subjects

A. Adedoyin, A. J. Wood, Hongwu Zhou, 1992, Clinical pharmacology and therapeutics.

Ultra‐short‐acting beta‐blockade: A comparison with conventional beta‐blockade

C. Reilly, A. Wood, M. Wood, 1985, Clinical pharmacology and therapeutics.

Effects of variation in the human α2A‐ and α2C‐adrenoceptor genes on cognitive tasks and pain perception

W. Dupont, M. Scheinin, C. Stein, 2010, European journal of pain.

Elemental Mercury Vapour Toxicity, Treatment, and Prognosis After Acute, Intensive Exposure in Chloralkali Plant Workers. Part I: History, Neuropsychological Findings and Chelator effects

L. W. Welch, R. Branch, R. G. Bobbitt, 1992, Human & experimental toxicology.

Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil

A. Wood, M. Hamilton, G. R. Avant, 1986, Clinical pharmacology and therapeutics.

Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects

R. Kim, J. Murray, C. Stein, 2001, Clinical pharmacology and therapeutics.

Interindividual differences in β‐receptor density contribute to variability in response to β‐adrenoceptor antagonists

Hong‐Hao Zhou, Alastair J. J. Wood, Honghao Zhou, 1989 .

Multiple pathways of propranolol's metabolism are inhibited by debrisoquin

A. Wood, L. Anthony, R. Koshakji, 1989, Clinical pharmacology and therapeutics.

Cimetidine inhibition of ethmozine metabolism

J. Biollaz, O. Shaheen, A. J. Wood, 1985, Clinical pharmacology and therapeutics.

Encainide disposition in patients with chronic cirrhosis

D. Roden, R. Bergstrand, R. Woosley, 1986, Clinical pharmacology and therapeutics.

α1A‐adrenergic Receptor Polymorphism and Vascular Response

R. Kim, Hong-Guang Xie, C. Stein, 2004 .

Elemental Mercury Vapour Toxicity, Treatment, and Prognosis After Acute, Intensive Exposure in Chloralkali Plant Workers. Part II: Hyperchloraemia and Genitourinary Symptoms

L. W. Welch, J. Breyer, R. Branch, 1992, Human & experimental toxicology.

Increased Baseline Sway Contributes to Increased Losses of Balance in Older People Following Triazolam

R. Shiavi, D. W. Robin, M. Lichtenstein, 1996, Journal of the American Geriatrics Society.

Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination

R. Branch, R. Vestal, G. Wilkinson, 1979, Clinical pharmacology and therapeutics.

Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten‐free diet: A potential source of interindividual variability in first‐pass drug metabolism

C. Lang, F. Guengerich, C. Lang, 1996, Clinical pharmacology and therapeutics.

Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long‐term dosing

P. G. Wells, G. Wilkinson, A. Wood, 1983, Clinical pharmacology and therapeutics.

Effect of CYP3A inhibition on vesnarinone metabolism in humans *

D. Flockhart, C. Wandel, S. Bramer, 1998, Clinical pharmacology and therapeutics.

Implementation of multiple outpatient formularies: Undesirable effects

T. Pincus, C. Stein, A. Wood, 1997, Clinical pharmacology and therapeutics.

Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole

G. Wilkinson, Y. Caraco, A. J. Wood, 1996, Clinical pharmacology and therapeutics.

Influence of debrisoquin phenotype on the inducibility of propranolol metabolism

J. Biollaz, G. Wilkinson, A. Wood, 1989, Clinical pharmacology and therapeutics.

Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect.

J. Murray, C. Stein, C. Stein, 1999, Clinical chemistry.

Effects of age and cigarette smoking on propranolol disposition

R. Branch, R. Vestal, G. Wilkinson, 1979, Clinical pharmacology and therapeutics.

Pharmacokinetics of Long Acting Propranolol Implications for Therapeutic Use

G. Nace, A. Wood, A. J. Wood, 1987, Clinical pharmacokinetics.

Molecular basis of ethnic differences in drug disposition and response.

R. Kim, C. Stein, C. Stein, 2001, Annual review of pharmacology and toxicology.

Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo.

R. Kim, C. Stein, P. Harris, 2001, Pharmacogenetics.

Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race.

C. Lang, C. Stein, C. Lang, 2001, Pharmacogenetics.

The Effects of Tadalafil on Cold‐induced Vasoconstriction in Patients with Raynaud's Phenomenon

C. Stein, P. Harris, C. Stein, 2007, Clinical pharmacology and therapeutics.

Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

G R Wilkinson, R. Kim, C. Wandel, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals.

J. Haines, R. Kim, Hong-hao Zhou, 1999, Pharmacogenetics.

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

D. Roden, R. Kim, M. Fromm, 1998, The Journal of clinical investigation.

Genetic variability in CYP3A5 and its possible consequences.

R. Kim, Hong-Guang Xie, C. Stein, 2004, Pharmacogenomics.

Biological determinants of propranolol disposition in man

R. Branch, R. Vestal, G. Wilkinson, 1978, Clinical pharmacology and therapeutics.

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.

R. Kim, A. Rettie, C. Stein, 2001, Molecular pharmacology.

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

R. Kim, F. Guengerich, C. Wandel, 1999, Cancer research.

Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.

P. Souček, F. Guengerich, A. Wood, 1997, Biochemical pharmacology.

Use of N-ethylmaleimide to directly determine the proportion of beta-adrenergic receptors exhibiting high affinity for agonists on human mononuclear leukocyte membranes.

A. Wood, J. Rigby, A. J. Wood, 1989, Biochemical pharmacology.

A common β1‐adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β‐blockade

U. B. Nair, P. Harris, C. Stein, 2003 .

Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites.

G R Wilkinson, H. Zhou, G. Wilkinson, 1989, The New England journal of medicine.

Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise

L. Ghimire, C. Stein, A. Wood, 2012, Pharmacogenetics and genomics.

Determination of catecholamines in sheep plasma by high-performance liquid chromatography with electrochemical detection: comparison of deoxyepinephrine and 3,4-dihydroxybenzylamine as internal standard.

Cynthia M. Stein, C. Stein, B. Christman, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Calcium Antagonists: Pharmacologic Differences and Similarities

A. J. Wood, 1989 .